Clinical Trials Sponsored by Merck Sharp & Dohme Corp.

Total 3966 results

Merck Sharp & Dohme LLC

Completed

Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)

Hypogonadism | Androgens
Merck Sharp & Dohme LLC

Terminated

3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer
Merck Sharp & Dohme LLC

Completed

Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)

Staphylococcal Infections
Merck Sharp & Dohme LLC

Completed

Bunionectomy Study (0000-063)

Acute Pain
Merck Sharp & Dohme LLC

Terminated

Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment

Retinal Detachment

United States
Merck Sharp & Dohme LLC

Completed

ProQuad Dose Selection Study (V221-011)(COMPLETED)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

Relapsed or Refractory Advanced Cancer
Merck Sharp & Dohme LLC

Completed

Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057)

Osteoarthritis, Knee
Merck Sharp & Dohme LLC

Terminated

Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease

Cystic Fibrosis
Merck Sharp & Dohme LLC

Completed

MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)

Neoplasm
Merck Sharp & Dohme LLC

Completed

Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)

Hepatitis B | Haemophilus Influenzae Type B
Merck Sharp & Dohme LLC

Completed

Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)

Crohn Disease
Merck Sharp & Dohme LLC

Completed

Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)

Neuromuscular Monitoring After Administration of Neuromuscular Blocking Agents in Different Types of Surgery
Merck Sharp & Dohme LLC

Completed

A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Cancer
Merck Sharp & Dohme LLC

Terminated

An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)

Obesity
Merck Sharp & Dohme LLC

Completed

Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)

Anesthesia
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)

Mycoses
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)

HIV Infections | Hepatitis C | Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)

Neoplasms
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)

Sarcopenia
Merck Sharp & Dohme LLC

Completed

A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

The Canadian Follow-up Program for the ATTRACT Study (P04868)(TERMINATED)

Arthritis, Rheumatoid
Merck Sharp & Dohme LLC

Terminated

An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)

Type 2 Diabetes Mellitus | Obesity Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)

Muscle Anabolism
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Terminated

A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED)

Obesity
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Chronic Myelogenous Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Merck Sharp & Dohme LLC

Completed

A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

Healthy | Pneumococcal Infections
Merck Sharp & Dohme LLC

Withdrawn

A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)

Varicella
Merck Sharp & Dohme LLC

Terminated

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Leukemia
Merck Sharp & Dohme LLC

Completed

Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])

Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer
Merck Sharp & Dohme LLC

Completed

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)

Dry Eye Disease
Merck Sharp & Dohme LLC

Withdrawn

Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)

Parkinson's Disease
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)

Osteoarthritis
Merck Sharp & Dohme LLC

Completed

A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)

Psychosis
Merck Sharp & Dohme LLC

Completed

A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).

Skin Androgenization
Merck Sharp & Dohme LLC

Withdrawn

An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN) (PEGIMPACT)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

Blepharitis

United States
Merck Sharp & Dohme LLC

Completed

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

Bacterial Conjunctivitis

United States
Merck Sharp & Dohme LLC

Terminated

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)

Blepharitis
Merck Sharp & Dohme LLC

Completed

A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)

Postoperative Nausea and Vomiting

3

Subscribe